Completed × Erlotinib Hydrochloride × Genitourinary × Clear all A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Phase 2 Completed
83 enrolled 17 charts
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Phase 1 Completed
95 enrolled
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Phase 2 Completed
673 enrolled 22 charts
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
Phase 2 Completed
34 enrolled 9 charts
Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer
Phase 2 Completed
1 enrolled
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
Phase 2 Completed
17 enrolled
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
Phase 2 Completed
55 enrolled 16 charts
Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer
Phase 2 Completed
29 enrolled 8 charts
Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer
Phase 2 Completed
27 enrolled 12 charts
Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
Phase 2 Completed
60 enrolled 10 charts
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Phase 4 Completed
54 enrolled
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
Phase 1/2 Completed
66 enrolled
A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma
Phase 2 Completed
100 enrolled
Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
Phase 2 Completed
25 enrolled 9 charts
OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma
Phase 2 Completed
63 enrolled
OSI-774
Phase 2 Completed
41 enrolled 7 charts
Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer
Phase 2 Completed
40 enrolled
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Phase 1/2 Completed
94 enrolled 7 charts
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase 1 Completed
75 enrolled
Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy
Phase 2 Completed
29 enrolled